Agios Pharmaceuticals Inc (AGIO) CEO Sells $3,877,480.00 in Stock
Agios Pharmaceuticals Inc (NASDAQ:AGIO) CEO David P. Schenkein sold 53,000 shares of the firm’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $73.16, for a total value of $3,877,480.00. Following the completion of the sale, the chief executive officer now directly owns 53,000 shares of the company’s stock, valued at $3,877,480. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Agios Pharmaceuticals Inc (NASDAQ AGIO) traded down $6.31 during midday trading on Tuesday, hitting $68.80. The stock had a trading volume of 1,175,807 shares, compared to its average volume of 710,071. The stock has a market cap of $3,440.00, a PE ratio of -10.97 and a beta of 1.83. Agios Pharmaceuticals Inc has a fifty-two week low of $39.24 and a fifty-two week high of $76.02.
Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.78) by $0.19. The business had revenue of $11.35 million during the quarter, compared to analysts’ expectations of $10.85 million. Agios Pharmaceuticals had a negative return on equity of 69.64% and a negative net margin of 506.39%. The company’s revenue was up 26.4% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.63) EPS. equities analysts forecast that Agios Pharmaceuticals Inc will post -6.59 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. California Public Employees Retirement System grew its holdings in shares of Agios Pharmaceuticals by 2.3% during the 2nd quarter. California Public Employees Retirement System now owns 34,900 shares of the biopharmaceutical company’s stock worth $1,796,000 after purchasing an additional 800 shares during the period. UBS Asset Management Americas Inc. grew its holdings in shares of Agios Pharmaceuticals by 3.2% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 27,088 shares of the biopharmaceutical company’s stock worth $1,394,000 after purchasing an additional 852 shares during the period. Amalgamated Bank grew its holdings in shares of Agios Pharmaceuticals by 12.9% during the 3rd quarter. Amalgamated Bank now owns 7,827 shares of the biopharmaceutical company’s stock worth $522,000 after purchasing an additional 897 shares during the period. Nationwide Fund Advisors grew its holdings in shares of Agios Pharmaceuticals by 37.8% during the 3rd quarter. Nationwide Fund Advisors now owns 6,344 shares of the biopharmaceutical company’s stock worth $423,000 after purchasing an additional 1,740 shares during the period. Finally, Principal Financial Group Inc. grew its holdings in shares of Agios Pharmaceuticals by 33.8% during the 2nd quarter. Principal Financial Group Inc. now owns 7,083 shares of the biopharmaceutical company’s stock worth $364,000 after purchasing an additional 1,789 shares during the period. Institutional investors and hedge funds own 94.32% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/16/agios-pharmaceuticals-inc-agio-ceo-sells-3877480-00-in-stock.html.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.